Early hepatic decompensation is the main driver of mortality in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib
作者
G. Cabibbo,C. Celsa,Salvatore Battaglia,M. Enea,G. Di Maria,Alessandro Grova,Roberta Ciccia,Giulia Francesca Manfredi,M. Iavarone,Arndt Vogel,A.G. Singal,María Reig,D.J. Pinato,C. Cammà